NCT01576380 - A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Adenocarcinoma, ScirrhousLinitis PlasticaStomach NeoplasmsStomach DiseasesNeoplasms by SiteNeoplasms

Interventions

DRUG

TKI258

TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.

Trial Locations (8)

Novartis Investigative Site, Nagoya

Novartis Investigative Site, Kashiwa

Novartis Investigative Site, Matsuyama

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Takatsuki

Novartis Investigative Site, Sunto-gun

Novartis Investigative Site, Chuo-ku

Novartis Investigative Site, Koto